COVID-19 IMPACT ON RESEARCH & TRIALS
While researchers may not be going into lab every day, they’re still hard at work to combat this disease. They may not be doing experiments at the bench, but they’re reading papers to develop their next idea, compiling data to better understand HD, and writing papers to disseminate what they’ve learned to the world. The labs may be quieter, but HD researchers are still hard at work in their fight against HD.
With many countries’ entire healthcare systems turned over to providing care for people with COVID illness, and many doctors and nurses diverted from research into frontline care, an impact on Huntington’s disease clinical trials is inevitable. However, all those involved are doing everything they can to minimize the impact and carry on with whatever trial activity they can.
In practice, the impact will vary quite a bit from one site to another, and from one trial to another. Some sites may still be enrolling new patients, while many will be forced to pause recruitment of new participants and focus on continued care and dosing of patients already involved. Many sites will likely convert onsite trial visits into telephone calls, or postpone visits until it is safer to carry them out in person.
Decisions about what activity can carry on are largely determined locally, by the hospitals and local and national governing bodies that direct healthcare resources. Trial sponsors (companies like Wave, Roche and UniQure) fund, support and organize the trials. So far, all the trial sponsors we’ve heard from have indicated that they continue to be committed to running and completing the trials despite the interruption the viral pandemic may cause. Learn more at www.HDBuzz.net.
Information from WHO
Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus.
Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness and recover without requiring special treatment. Older people, and those with underlying medical problems like cardiovascular disease, diabetes, chronic respiratory disease, and cancer are more likely to develop serious illness.
The best way to prevent and slow down transmission is be well informed about the COVID-19 virus, the disease it causes and how it spreads. Protect yourself and others from infection by washing your hands or using an alcohol based rub frequently and not touching your face.
The COVID-19 virus spreads primarily through droplets of saliva or discharge from the nose when an infected person coughs or sneezes, so it’s important that you also practice respiratory etiquette (for example, by coughing into a flexed elbow).
At this time, there are no specific vaccines or treatments for COVID-19. However, there are many ongoing clinical trials evaluating potential treatments. WHO will continue to provide updated information as soon as clinical findings become available.
COVID-19 IMPACT ON PEOPLE AFFECTED BY HUNTINGTON'S
In Italy, Scotland and Belgium the impact of COVID-19 have been studied. Isolation, concerns, pressure, but also closeness to beloved ones and support. Learn more about how Huntington families are affected and why support is so important.
There are many things you can join from the comfort of your own home
In this Webinar of May Awareness Month, Vissia Viglietta will be speaking on behalf of Wave Life Sciences. She would explain the results and all the good work they have been doing in improving from the updated on PRECISION-HD1 and PRECISION-HD2 medical trials. Wave would also present the promising approach that they are pursuing, the WVE-003 Project.
The WVE-003 Project
Wave is developing a third allele-selective HD candidate, WVE-003, which is designed to selectively target an undisclosed SNP on the mHTT mRNA transcript (SNP3), while leaving wtHTT protein relatively intact. In other words, Wave has the potential to provide allele-selective options for up to 80% of people with HD.
Speaker: Vissia Viglietta
Vice President Global Clinical Development and Medical Affairs at Wave Life Sciences
WHEN: 12. May, 19:00-20:30 Central European Time
Link here to register: https://bit.ly/3xp2ay2
The European Academy of Neurology (EAN) is hosting their 7th Congress in June 2021. This years theme: Towards Precision Neurology.
From Claudio L. Bassetti, EAN President:
“As the number of lives affected by the COVID-19 pandemic has now reached the millions, the health and safety of our congress attendees, our patients and our families, remains our primary concern.
While we may come from different nations, we are all experiencing difficult and trying times, and we must continue to work together to slow the spread of the disease.
With this situation in mind, the European Academy of Neurology has decided to go virtual again for the 7th EAN Congress on June 19-22, 2021, originally to be held in Vienna.
Once again, we look forward to offering you the opportunity to learn from experts in your field, grow your professional network, and discover the latest best practices in neurology, all in the comfort of your home. Building on our experience from the EAN Virtual Congress 2020, we will utilise the very best technical solutions to provide you with a virtual experience as comfortable and rewarding as the real thing.
In order to make participation affordable for colleagues all over the world, EAN is offering reduced fees for the virtual congress.
Please find detailed information on the EAN Congress Website.”
Registration is now open!
Cost per ticket depends on whether you are a EAN member or not and your membership (student, researcher, etc.).